News
Breast cancer: NICE approves new drug combination treatment
BMJ 2019; 366 doi: https://doi.org/10.1136/bmj.l4727 (Published 17 July 2019) Cite this as: BMJ 2019;366:l4727
- Elisabeth Mahase
- The BMJ
A new drug combination option for some patients with advanced breast cancer will now be available through the Cancer Drugs Fund, say new draft guidelines from the National Institute for Health and Care Excellence (NICE).1
The guidance has recommended ribociclib (Kisqali) with fulvestrant as an option for people with hormone receptor positive, human epidermal growth factor receptor 2 negative, locally advanced or metastatic breast cancer who have had previous endocrine therapy.
Ribociclib, a CDK4/6 …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.